NYSE - Nasdaq Real Time Price USD

Teva Pharmaceutical Industries Limited (TEVA)

13.40

+0.15

(+1.13%)

As of 10:45 AM EDT. Market Open.

UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.

Reuters 3 days ago

VNDA

TEVA
+1.13%
11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]

Insider Monkey 5 days ago

^GSPC

AZN
-0.16%
SWAV
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.

Zacks 7 days ago

TEVA
+1.13%
VTRS

^GSPC
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.

Zacks 7 days ago

TEVA
+1.13%
^GSPC

VTRS
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under

Business Wire 9 days ago

TEVA
+1.13%
TEVJF

ALVO
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

TEL AVIV, Israel & PARSIPPANY, N.J., April 16, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body

Business Wire 10 days ago

TEVA
+1.13%
TEVJF
Israeli economy has proven to thrive despite crisis: Expert

Over the weekend, Iran launched a direct attack on Israel. Although Israel successfully intercepted the drones and missiles, the potential for an Israeli retaliation remains uncertain. David Blumberg of Blumberg Capital joins Yahoo Finance to discuss the state of the Israeli economy in light of these developments. Blumberg claims that Israelis are "somewhat used to these types of things." Blumberg notes that over the past 25 years, the country has weathered numerous crises, but has achieved consistent growth. He points to Israel's GDP per capita of $54,000, which exceeds that of some of the world's largest economies, as evidence of the economy's ability to "thrive despite and through downturns." For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

Yahoo Finance Video 10 days ago

NTNX

CHKP

DV
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

TEL AVIV, Israel & PARSIPPANY, N.J., April 11, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

Business Wire 15 days ago

TEVA
+1.13%
TEVJF
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

TEL AVIV, Israel, April 09, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Business Wire 16 days ago

TEVA
+1.13%
TEVJF
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

TEL AVIV, Israel & PARSIPPANY, N.J., April 06, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults. The data were presented at the 2024 Congress of the Schizophrenia Inte

Business Wire 19 days ago

TEVA
+1.13%
TEVJF
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

TEL AVIV, Israel, & MADRID, April 04, 2024--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective altern

Business Wire 22 days ago

TEVA
+1.13%
TEVJF
3 No-Brainer Stocks to Buy With $600 Right Now

A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.

Motley Fool 23 days ago

O

TEVA
+1.13%
SQ
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers

U.S. President Joe Biden will host a White House event with U.S. Senator Bernie Sanders on Wednesday to highlight their efforts to cut the cost of inhalers for asthma suffers. Sanders and other lawmakers in January criticized four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals (TEVA.TA), and GSK (GSK.L), — over prices that were much higher in the U.S. than in other countries. The Biden administration has also sought to crack down on what it calls falsely claimed patents in an effort to increase competition to lower inhaler costs.

Reuters 23 days ago

TEVA
+1.13%
AZN
-0.16%
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."

Reuters 24 days ago

TEVA
+1.13%
VTRS

JNJ
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit said that the last remaining J&J patent covering its Invega Sustenna may be invalid, sending the case back for a New Jersey federal court to reconsider. A J&J spokesperson said the company will "continue defending the intellectual property of Invega Sustenna."

Reuters 24 days ago

VTRS

TEVA
+1.13%
JNJ
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

LONDON & BOSTON & TEL AVIV, Israel, April 01, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today also announced a strategic development funding agreement in which Abingworth provides Tev

Business Wire 25 days ago

TEVA
+1.13%
TEVJF

CG
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 29 days ago

BHC

TEVA
+1.13%
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership

Key Insights Given the large stake in the stock by institutions, Teva Pharmaceutical Industries' stock price might be...

Simply Wall St. last month

TEVA
+1.13%
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.

Zacks last month

CORT

TEVA
+1.13%
25 Countries with the Lowest Fertility Rates

In this article, we will be taking a look at the 25 countries with the lowest fertility rates. If you do not want to learn about the global infertility market, head straight to the 6 Countries with the Lowest Fertility Rates. Countries with the lowest fertility rates like Hong Kong, Macau, Singapore, and Taiwan, among […]

Insider Monkey last month

CHD

TEVA
+1.13%

Performance Overview

Return	TEVA	TA-125
YTD	+28.35%	+3.84%
1-Year	+62.82%	+12.73%
3-Year	+30.86%	+14.62%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA)

UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

11 Best Low Price Pharma Stocks To Invest In

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris

3 Generic Drug Stocks to Watch Amid Challenging Market Prospects

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

Israeli economy has proven to thrive despite crisis: Expert

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

3 No-Brainer Stocks to Buy With $600 Right Now

Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers

UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?

Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership

Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

25 Countries with the Lowest Fertility Rates

Performance Overview